Rebalancing the Gut: Glucagon-Like Peptide-1 Agonists as a Strategy for Obesity and Metabolic Health.
重新平衡腸道:Glucagon-Like Peptide-1 受體激動劑作為肥胖和代謝健康的策略。
Cureus 2024-08-19
GLP-1 receptor agonists for the treatment of obesity: Role as a promising approach.
GLP-1 受體激動劑用於肥胖治療:作為一種有前途的方法。
Front Endocrinol (Lausanne) 2023-11-06
Synergistic Combinations of Gut- and Pancreas-Hormone-Based Therapies: Advancements in Treatments for Metabolic Diseases.
腸道和胰臟荷爾蒙療法的協同組合:代謝性疾病治療的進展。
Endocrinology 2023-11-11
Glucagon-like peptide-1 receptor agonist regulates fat browning by altering the gut microbiota and ceramide metabolism.
葡萄糖樣肽-1 受體激動劑通過改變腸道菌群和神經酰胺代謝調節脂肪棕化。
MedComm (2020) 2023-12-01
Role of lifestyle and glucagon-like peptide-1 receptor agonists for weight loss in obesity, type 2 diabetes and steatotic liver diseases.
生活方式和胰高血糖素樣肽-1受體激動劑在肥胖症、2型糖尿病和脂肪肝疾病中減重的作用。
Aliment Pharmacol Ther 2024-05-30
Energy balance and obesity: the emerging role of glucagon like peptide-1 receptor agonists.
能量平衡與肥胖:胰高血糖素樣肽-1 受體激動劑的新興角色。
Curr Opin Clin Nutr Metab Care 2024-08-16